ArticleNeurosurgical review2025
The role of chemotherapy in patients with gliomatosis cerebri: a population-based study.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gliomatosis Cerebri (GC) is a rare and aggressively infiltrative diffuse glioma with a grim prognosis. The efficacy of chemotherapy in GC is controversial. This study aimed to assess the impact of chemotherapy on GC patients in a population-based cohort. Patients with Gliomatosis Cerebri (GC) diagnosed between 2000 and 2021 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier survival curves were utilized and compared using the log-rank test to assess survival disparities. Cox regression analysis was employed to identify prognostic factors, with the results of the multivariate analysis presented in a forest plot. Subgroup analyses were then performed to discern which patient subgroups might potentially benefit from chemotherapy. Our cohort comprised 227 GC patients, with median cause-specific survival (CSS) was 11 months (95% Confidence Interval [CI],9-16 months) and a 5-year survival rate of 12.8%. Restrictive cubic splines (RCS) regression analysis indicated a significant linear correlation between advancing age and CSS (P
Indexed as
Identifiers
40314840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.